Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study by Ren, Zhenggang, Prof, Xu, Jianming, Prof, Bai, Yuxian, Prof, Xu, Aibing, Prof, Cang, Shundong, Prof, Du, Chengyou, Prof, Li, Qiu, Prof, Lu, Yinying, Prof, Chen, Yajin, Prof, Guo, Yabing, Prof, Chen, Zhendong, Prof, Liu, Baorui, Prof, Jia, Weidong, Prof, Wu, Jian, Prof, Wang, Junye, Prof, Shao, Guoliang, Prof, Zhang, Bixiang, Prof, Shan, Yunfeng, Prof, Meng, Zhiqiang, Prof, Wu, Jianbing, Prof, Gu, Shanzhi, Prof, Yang, Wei, Prof, Liu, Chao, Prof, Shi, Xuetao, Prof, Gao, Zhenyuan, Prof, Yin, Tao, Prof, Cui, Jiuwei, Prof, Huang, Ming, Prof, Xing, Baocai, Prof, Mao, Yilei, Prof, Teng, Gaojun, Prof, Qin, Yanru, Prof, Wang, Jinhai, Prof, Xia, Feng, Prof, Yin, Guowen, Prof, Yang, Yong, MD, Chen, Mingxia, MD, Wang, Yan, MD, Zhou, Hui, MD, Fan, Jia, Prof

Get full text

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial by Qin, Shukui, Prof, Ren, Zhenggang, Prof, Meng, Zhiqiang, Prof, Chen, Zhendong, Prof, Chai, Xiaoli, Prof, Xiong, Jianping, Prof, Bai, Yuxian, Prof, Yang, Lin, Prof, Zhu, Hong, MD, Fang, Weijia, Prof, Lin, Xiaoyan, Prof, Chen, Xiaoming, MD, Li, Enxiao, Prof, Wang, Linna, MD, Chen, Chunxia, MSc, Zou, Jianjun, MD

Get full text